eP213: Phase 2 multiple ascending-dose study of SRP-5051 PPMO in patients with DMD amenable to exon 51 skipping: Part A results
Craig Campbell(Western University), H. Phan(Rare Disease Therapeutics (United States)), Jyoti Malhotra(City Of Hope National Medical Center), Katherine D. Mathews(University of Iowa), Marc van de Rijn(Sarepta Therapeutics (United States)), Emanuel Palatinsky(Sarepta Therapeutics (United States)), Erin O’Rourke(Sarepta Therapeutics (United States)), Ihor Sehinovych(Sarepta Therapeutics (United States)), Jon Tinsley(Summit (United Kingdom)), Xiao Ni(Sarepta Therapeutics (United States)), Nanshi Sha(Sarepta Therapeutics (United States))
Cited by 2
Related Papers
Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort
|Human Mutation|2009|314
<i><scp>LTBP4</scp></i> genotype predicts age of ambulatory loss in duchenne muscular dystrophy
|Annals of Neurology|2012|242
Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy
|Human Mutation|2012|137
Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy
|Pediatric Cardiology|2005|125